ArticleAmerican journal of translational research2026
Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study intended to clarify the role of metoprolol-spironolactone combination in treating coronary heart disease (CHD) with concurrent heart failure (HF), focusing on its impact on cardiac function.
methodsA total of 100 CHD + HF patients were selected, including 50 cases in the control group treated with spironolactone and 50 cases in the research group given metoprolol + spironolactone. Cardiac function (left ventricular end-systolic diameter [LVESd], left ventricular end-diastolic diameter [LVEDd], left ventricular ejection fraction [LVEF]), cardiac function classification, serum brain natriuretic peptide (BNP), oxidative stress (superoxide dismutase [SOD], malondialdehyde [MDA]), inflammation, hemodynamics (cardiac index/output), effectiveness, and safety were analyzed.
resultsThe combination therapy induced a more evident reduction in LVESd, LVEDd, BNP, MDA, and two inflammatory cytokines than spironolactone alone, as well as a greater rise in LVEF, SOD, cardiac index, and cardiac output. The research group also showed superior improvements in cardiac function classification and clinical efficacy, as well as a lower overall adverse effect rate.
conclusionMetoprolol-spironolactone combination is remarkably effective in treating CHD + HF and significantly improve patients' cardiac function, which merits clinical popularization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.